Skip to main content

Matthew Kelly

Adjunct Associate Professor of Pediatrics
Pediatrics, Infectious Diseases

Overview


My research is broadly focused on elucidating the complex interactions that exist between the host microbiome and exogenous pathogens that cause infections in children. We have several ongoing projects evaluating: 1) the impact of the upper respiratory microbiome on the risk of colonization and invasion by bacterial respiratory pathogens among infants in Botswana; 2) associations between the gut microbiome of pediatric stem cell transplant recipients and the risk of infections (bloodstream infection, C. difficile infection) and graft-versus-host disease; and 3) the role of the gut and respiratory microbiomes in mediating COVID-19 infection susceptibility and disease severity in children. Ultimately, I aim to develop strategies that use targeted modification of the microbiome for the prevention of infections in children.

Current Appointments & Affiliations


Adjunct Associate Professor of Pediatrics · 2025 - Present Pediatrics, Infectious Diseases, Pediatrics
Member of the Human Vaccine Institute · 2024 - Present Duke Human Vaccine Institute, Institutes and Centers

In the News


Published February 23, 2024
Nasal Probiotic May Reduce Child Respiratory Infections
Published February 16, 2023
A Promising New Approach Against a Forgotten Killer
Published July 16, 2021
Children With Mild or Asymptomatic COVID Have Strong Antibodies Months Later

View All News

Recent Publications


Global Assessment of Health Utilities Associated with Pneumococcal Disease in Adults: Targeted Literature Reviews.

Journal Article Pharmacoecon Open · December 10, 2025 BACKGROUND: Pneumococcal disease can significantly reduce quality of life (QoL). Health utilities are commonly used to assess QoL burden and calculate quality-adjusted life years (QALYs), which are critical inputs in cost-utility analyses (CUAs) to evaluat ... Full text Link to item Cite

Comprehensive Assessment of the Intrinsic Pancreatic Microbiome.

Journal Article Ann Surg · December 1, 2025 OBJECTIVE: To sought comprehensively profile tissue and cyst fluid in patients with benign, precancerous, and cancerous conditions of the pancreas to characterize the intrinsic pancreatic microbiome. BACKGROUND: Small studies in pancreatic ductal adenocarc ... Full text Link to item Cite

Real-world outcomes of infections following tisagenlecleucel in patients with B-cell ALL: a CIBMTR analysis.

Journal Article Blood Adv · November 11, 2025 Tisagenlecleucel (tisa-cel) is a CD19-directed chimeric antigen receptor T-cell therapy for relapsed/refractory precursor B-cell acute lymphoblastic leukemia (R/R B-ALL). We report infectious complications for 100 days (D100) following tisa-cel therapy in ... Full text Link to item Cite
View All Publications

Recent Grants


Role of C difficile Colonization in Risk of Disease

ResearchCo-Mentor · Awarded by National Institutes of Health · 2025 - 2030

Unified Program for Therapeutics in Children

Inst. Training Prgm or CMEPreceptor · Awarded by National Institutes of Health · 2025 - 2030

View All Grants

Education, Training & Certifications


Harvard Medical School · 2007 M.D.
Harvard University · 2007 M.P.H.